# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Malignant peripheral nerve sheath tumor

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 75 results.
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Status: Recruiting
Last Changed: Dec 05, 2019
First Received: May 04, 2017
Disease(s): Malignant Peripheral Nerve Sheath Tumors
Locations: Moffitt Cancer Center, Tampa, Florida, United States
Johns Hopkins, Baltimore, Maryland, United States
National Institutes of Health (NIH), Bethesda, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Minnesota, Minneapolis, Minnesota, United States
... and 7 other locations.
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Status: Active, not recruiting
Last Changed: Mar 13, 2019
First Received: Feb 24, 2016
Disease(s): Malignant Peripheral Nerve Sheath Tumour (MPNST)
Intervention(s): Pembrolizumab
Locations: Oslo university Hospital, Oslo, Norway
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Status: Terminated
Last Changed: Aug 07, 2012
First Received: Jan 29, 2007
Disease(s): Malignant Peripheral Nerve Sheath Tumors
Intervention(s): imatinib mesylate
Locations: Novartis Investigative Site, Berlin, Germany
Novartis Investigative Site, Hamburg, Germany
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Status: Recruiting
Last Changed: Jun 07, 2019
First Received: Oct 22, 2015
Disease(s): Sarcoma, Malignant Peripheral Nerve Sheath Tumors
Intervention(s): PLX3397, Sirolimus
Locations: Early Drug Development Center, Boston, Massachusetts, United States
Washington University in St. Louis, Saint Louis, Missouri, United States
Columbia University, New York, New York, United States
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Status: Active, not recruiting
Last Changed: Jan 29, 2020
First Received: Feb 14, 2018
Disease(s): Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
Intervention(s): Selumetinib, Sirolimus
Locations: Children's National Medical Center, Washington, District of Columbia, United States
Johns Hopkins University, Baltimore, Maryland, United States
National Cancer Institute, Bethesda, Maryland, United States
Washington University, Saint Louis, Missouri, United States
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Status: Completed
Last Changed: May 15, 2019
First Received: Dec 11, 2013
Disease(s): Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
Intervention(s): ganetespib, Sirolimus
Locations: Sarcoma Oncology Center, Santa Monica, California, United States
Children's National Medical Center, Washington, District of Columbia, United States
University of Iowa, Iowa City, Iowa, United States
National Cancer Institute, Bethesda, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
... and 3 other locations.
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Status: Recruiting
Last Changed: Apr 08, 2019
First Received: Mar 07, 2016
Disease(s): Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor
Intervention(s): Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
Locations: Mayo Clinic, Rochester, Minnesota, United States
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Completed
Last Changed: Mar 06, 2019
First Received: Aug 09, 2012
Disease(s): Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
Intervention(s): everolimus, bevacizumab
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Children's National Medical Center, Washington, District of Columbia, United States
Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Johns Hopkins, Baltimore, Maryland, United States
... and 8 other locations.
Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors
Status: Withdrawn
Last Changed: Sep 11, 2018
First Received: Dec 08, 2016
Disease(s): Peripheral Nerve Tumors
Intervention(s): CPI-0610
Locations: University of Texas Southwestern Medical Center, Dallas, Texas, United States
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Status: Active, not recruiting
Last Changed: Aug 29, 2019
First Received: May 22, 2015
Disease(s): Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor
Intervention(s): Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study
Locations: Children's Hospital of Alabama, Birmingham, Alabama, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center, Downey, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
... and 65 other locations.